AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Griknil M 2mg/500mg Tablet SR

Prescription Icon
Prescription Required

Marketer

Aplonis Healthcare

Salt Composition

Glimepiride (2mg) + Metformin (500mg)

Overview Griknil M 2mg/500mg Tablet SR

DiaBeta-Duo 2mg/500mg Extended-Release tablets are classified as antidiabetic agents. This dual-action medication treats type 2 diabetes in adults by regulating blood glucose. DiaBeta-Duo should be administered with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on blood sugar monitoring. Continued use is vital, even with controlled blood sugar, as discontinuation without medical consultation risks elevated glucose levels, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. This medication forms part of a comprehensive diabetes management plan including diet, exercise, and weight management as recommended by your doctor. Lifestyle choices significantly impact diabetes control. Hypoglycemia (low blood sugar) is the most prevalent side effect, characterized by symptoms like sweating, dizziness, headache, and tremors. Prompt glucose intake (e.g., sugary foods, fruit juice) is crucial. Alcohol consumption should be minimized due to increased hypoglycemia risk. Additional potential side effects include altered taste, nausea, diarrhea, abdominal pain, headache, and upper respiratory infections. Weight gain may occur. This medication is contraindicated for type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Prior heart conditions should be disclosed to your physician before commencement. Pregnant or lactating women require medical consultation. Regular blood glucose monitoring, along with periodic blood tests (blood cell counts and liver function), are recommended by your physician.

Uses of Griknil M 2mg/500mg Tablet SR

Managing type 2 diabetes

Major Benefits of Griknil M 2mg/500mg Tablet SR:

Administer this medication precisely as your physician directs, adhering to the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Consume Griknil M 2mg/500mg Extended-Release tablets with food.

Common Side effects of Griknil M 2mg/500mg Tablet SR:

  • Headache
  • Hypoglycemia (low blood glucose level)
  • Nausea
  • Diarrhea

How to use Griknil M 2mg/500mg Tablet SR:

Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the Griknil M 2mg/500mg Tablet SR whole; avoid crushing, chewing, or breaking it. Administer this extended-release tablet with a meal.

How Griknil M 2mg/500mg Tablet SR works:

Griknil M SR tablets (2mg/500mg) contain glimepiride and metformin, two antidiabetic agents. Glimepiride, a sulfonylurea, stimulates pancreatic insulin secretion to reduce blood glucose. Metformin, a biguanide, acts by decreasing hepatic glucose production, impeding intestinal glucose absorption, and enhancing insulin sensitivity.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent alcohol use and Griknil M 2mg/500mg SR tablets is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

Using Griknil M 2mg/500mg SR tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the unborn child. A physician will assess the advantages against possible risks prior to prescription. Seek medical advice.

Breast feedingBreast feedingUNSAFE

Extended-release Griknil M tablets (2mg/500mg) are contraindicated during lactation due to the potential for infant toxicity.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Exercise caution when administering Griknil M 2mg/500mg SR tablets to individuals with impaired renal function; dosage modification may be necessary. Consult a physician for guidance. Griknil M 2mg/500mg SR tablets are contraindicated in patients exhibiting severe kidney disease. Close monitoring of renal function is recommended throughout the treatment period.

LiverLiverCAUTION

Exercise caution when administering Griknil M 2mg/500mg SR tablets to individuals with hepatic impairment. Dosage modification of Griknil M 2mg/500mg SR tablets may be necessary. Physician consultation is advised. Initiate Griknil M 2mg/500mg SR treatment with a reduced dosage in patients exhibiting mild to moderate liver dysfunction; its use is contraindicated in those with severe hepatic disease.

What if you forget to take Griknil M 2mg/500mg Tablet SR :

Should you forget to take a Griknil M 2mg/500mg Tablet SR, ingest it immediately upon recollection. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing pattern. Avoid taking a double dose.

Facts to Know About Griknil M 2mg/500mg Tablet SR

LabelValue
Potential for Dependence None.
Treatment Category Medication for diabetes

FAQs on Griknil M 2mg/500mg Tablet SR

Retain this medication within its original, sealed container or packaging. Follow the storage guidelines printed on the packaging or label. Discard any leftover medication. Ensure it remains inaccessible to children, pets, and others.
Griknil M 2mg/500mg Tablet SR use may result in lactic acidosis, a serious medical condition characterized by excessive blood lactic acid. Also termed MALA (Metformin-associated lactic acidosis), this rare adverse reaction is particularly risky for individuals with kidney impairment, the elderly, or those who consume substantial alcohol. Symptoms can manifest as muscle aches or weakness, lightheadedness, fatigue, cold extremities, respiratory distress, nausea, vomiting, abdominal discomfort, or bradycardia. Should these symptoms appear, discontinue Griknil M 2mg/500mg Tablet SR and seek immediate medical attention.
Griknil M 2mg/500mg Extended-Release tablets contain glimepiride and metformin, two medications used together to manage type 2 diabetes mellitus in adults. This dual therapy helps regulate blood sugar when combined with a suitable diet and consistent physical activity. Glimepiride enhances insulin secretion from the pancreas, thus reducing blood glucose. Metformin reduces hepatic glucose production and enhances insulin effectiveness. This formulation is unsuitable for treating type 1 diabetes mellitus.
Griknil M 2mg/500mg sustained-release tablets may cause common side effects including low blood sugar, taste changes, nausea, abdominal discomfort, diarrhea, and headache. Rare but serious adverse reactions such as lactic acidosis are also possible. Prolonged administration may result in vitamin B12 deficiency.
Prolonged Griknil M 2mg/500mg Tablet SR administration can indeed lead to Vitamin B12 deficiency. This medication impedes Vitamin B12 absorption within the gastrointestinal tract. Untreated deficiency may result in anemia, neurological complications such as paresthesia in the extremities, generalized weakness, urinary dysfunction, cognitive impairment, and gait instability. To mitigate these risks, supplemental Vitamin B12 intake, at a minimum, annually, has been proposed by some investigators.
Indeed, Griknil M 2mg/500mg Extended-Release Tablets may induce hypoglycemia. Low blood sugar can manifest as nausea, headache, irritability, hunger pangs, sweating, vertigo, tachycardia, and feelings of anxiety or tremor. This risk increases with skipped or delayed meals, alcohol consumption, excessive physical activity, or concomitant use of other antidiabetic medications. Consequently, consistent blood glucose monitoring is crucial. Carrying a readily available fast-acting carbohydrate source, such as glucose tablets, honey, or fruit juice, is recommended.
Combining Griknil M 2mg/500mg sustained-release tablets and alcohol is unsafe. This combination can cause dangerously low blood sugar (hypoglycemia) and raise the risk of lactic acidosis.
Griknil M 2mg/500mg Table...
56
MRP 68
17% off